drugset / Trial / NCT06451211
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.
Timeline
- Start
- 2023-05-17
- Primary completion
- 2024-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 2500 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 150 mg | — |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |